ID: ALA5197285

Max Phase: Preclinical

Molecular Formula: C40H53N7O5S

Molecular Weight: 743.97

Representations

Canonical SMILES:  CN(C(=O)C1CCN(C(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](CCc2ccccc2)C(=O)N[C@@H]2CCCc3ccccc32)CC1)c1nccs1

Standard InChI:  InChI=1S/C40H53N7O5S/c1-40(2,3)26-42-34(48)25-33(45-38(52)47-22-19-29(20-23-47)37(51)46(4)39-41-21-24-53-39)36(50)44-32(18-17-27-11-6-5-7-12-27)35(49)43-31-16-10-14-28-13-8-9-15-30(28)31/h5-9,11-13,15,21,24,29,31-33H,10,14,16-20,22-23,25-26H2,1-4H3,(H,42,48)(H,43,49)(H,44,50)(H,45,52)/t31-,32+,33+/m1/s1

Standard InChI Key:  CUBBVLUICVMVCH-CEUYOYMZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 743.97

Molecular Weight (Monoisotopic): 743.3829

AlogP: 4.76

#Rotatable Bonds: 13

Polar Surface Area: 152.84

Molecular Species: NEUTRAL

HBA: 7

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.56

CX Basic pKa:

CX LogP: 4.16

CX LogD: 4.16

Aromatic Rings: 3

Heavy Atoms: 53

QED Weighted: 0.20

Np Likeness Score: -1.08

References

1. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source

Source(1):

• Scientific Literature